Meeting
2019 ASCO Annual Meeting
KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results.
Authors
Peter H. O'Donnell
The University of Chicago, Chicago, IL
Peter H. O'Donnell , Arjun Vasant Balar , Jacqueline Vuky , Daniel E. Castellano , Joaquim Bellmunt , Thomas Powles , Dean F. Bajorin , Petros Grivas , Noah M. Hahn , Elizabeth R. Plimack , Mary J. Savage , Xiao Fang , James Luke Godwin , Tara L. Frenkl , Ronald De Wit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT02335424
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4546)
DOI
10.1200/JCO.2019.37.15_suppl.4546
Abstract #
4546
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
First Author: Jacqueline Vuky
Poster
2021 ASCO Annual Meeting
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
First Author: Terence W. Friedlander
Poster
2020 Genitourinary Cancers Symposium
ABLE: single-arm trial of nab-paclitaxel with ANTI-PD1 in advanced urothelial cancer.
First Author: Jason Brown
Poster
2019 ASCO Quality Care Symposium
Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.
First Author: Yizhen Lai